SATELLITE SYMPOSIA
Dry AMD & GA IME Platform: Understanding Emerging Treatment Approaches for dry AMD and Geographic Atrophy
1 September, 13:15 – 14:15 CEST
Hall 3
Chairperson(s): F. Holz GERMANY
Management of diabetic macular edema: Bridging the real-world efficacy gap
1 September, 13:15 – 14:15 CEST
Hall 4
Chairperson(s): A. Loewenstein ISRAEL & L. Kodjikian FRANCE
Photobiomodulation Preclinical Mechanisms to Clinical Application: US Pivotal LIGHTSITE III Trial Results in Intermediate dry AMD Patients
1 September, 13:15 – 14:15 CEST
Hall G1
Chairperson(s): M. Munk AUSTRIA
DME Treatment Fundamentals IME Platform: Improving Visual Outcomes in DME Patients with Current and Emerging Treatments
2 September, 09.45 - 10.45 CEST
Hall 3
Chairperson(s):
R. Schlingemann NETHERLANDS
Recent Advances in Multimodal Imaging and Artificial intelligence in Ophthalmology
2 September, 09.45 - 10.45 CEST
Hall G1
Chairperson(s):
S. Srinivas USA
Smaller, Faster, Closer - Precision in Retina Surgeries
2 September, 09.45 - 10.45 CEST
Hall G2
Chairperson(s):
F. Patelli ITALY
UWF Multimodal Imaging and Microperimetry – Enhancing the Bridge between Structure and Function
2 September, 09.45 - 10.45 CEST
Hall X1
Chairperson(s):
R. Abreu Gonzalez SPAIN
Heidelberg AppWay: Secure workflow solution for access to ophthalmic applications and AI algorithms
2 September, 13.45 - 14.45 CEST
Hall E
Chairperson(s): C. Mody UK
Advancing the management of nAMD: Latest clinical insights from targeting Ang-2/VEGF-A via dual inhibition
2 September, 13.45 - 14.45 CEST
Hall 3
Chairperson(s):
F. Holz GERMANY
How LASER has changed since coronavirus struck ?
2 September, 13.45 - 14.45 CEST
Hall X1
Chairperson(s):
V. Chong UK
Reducing the burden of DME – what matters in clinical management?
2 September, 13.45 - 14.45 CEST
Hall G1
Chairperson(s):
A. Loewenstein ISRAEL
Benefits beyond vision: 10 years of delivering outcomes that matter
2 September, 13.45 - 14.45 CEST
Hall 4
Chairperson(s):
A. Stahl GERMANY
Evolving Management in Diabetic Macula Edema
2 September, 13.45 - 14.45 CEST
Hall G2
Chairperson(s):
D. Zur ISRAEL,
M. Iglicki ARGENTINA
OCTA-A Innovations: deeper, wider, and beyond Ophthalmology TBC
2 September, 13.45 - 14.45 CEST
Hall X2
Chairperson(s): M. Munk SWITERLAND
Expert clinical insights: How continuous delivery of anti-VEGF is changing the management of nAMD
2 September, 17.45 - 18.45 CEST
Hall X2
Chairperson(s):
A. Wolf GERMANY
EVA NEXUS™: The Future of Ophthalmic Surgery
2 September, 18.15 - 19.15 CEST
Hall G1
Chairperson(s):
G. Pertile ITALY
MicroPulse® and PASCAL® in the world of retinal treatments
3 September, 09.45 - 10.45 CEST
Hall E
Chairperson(s):
S. Vujosevic ITALY
Durability across indications: Seeing from the patient's perspective
3 September, 09:45 - 10:45 CEST
Hall 4
Chairperson(s):
G. Cheung SINGAPORE &
V. Chaudhary CANADA
A vision of the future: The next level in patient care
3 September, 13.45 - 14.45 CEST
Hall 1
Chairperson(s):
N. Eter GERMANY
Broadening management options for DME: Recent clinical insights from targeting dual inhibition of Ang-2 and VEGF-A
3 September, 13.45 - 14.45 CEST
Hall 3
Chairperson(s):
J-F Korobelnik FRANCE
Wide field swept source OCT: Learn from our experts!
3 September, 13.45 - 14.45 CEST
Hall X1
Chairperson(s):
P. Stanga UK
Preserving patient health: the retina and beyond
3 September, 13.45 - 14.45 CEST
Hall G1
Chairperson(s):
C. Delcourt FRANCE & T. Aslam UK
Driving Efficiency & Performance through Visionary Technology
3 September, 13.45 - 14.45 CEST
Hall E
Chairperson(s):
T. Williamson UK
Experience From The Clinic: Management of Neovascular AMD Patients in 2022
3 September, 13.45 - 14.45 CEST
Hall 4
Chairperson(s):
R. Khoramnia GERMANY
Fine-Tune your Vitreoretinal Surgery – How to get the best view for you and your patients
3 September, 13.45 - 14.45 CEST
Hall X2
Chairperson(s):
P. Stalmans BELGIUM
The future of geographic atrophy: advancing diagnosis, treatment and management
3 September, 13.45 - 14.45 CEST
Hall G2
Chairperson(s):
P. Udaondo SPAIN
nAMD Treatment Fundamentals IME Platform: Pearls for a Proactive and Individualized nAMD Treatment Approach with Modern Therapeutics
3 September, 17.45 - 18.45 CEST
Hall 4
Chairperson(s):
A. Loewenstein ISRAEL
Retinale® – EURETINA Kompakt
3 September, 17.45 - 18.45 CEST
Hall X2
Chairperson(s):
N. Feltgen GERMANY
